TCNJ

40 The College of New Jersey Magazine competitive multiyear, multimillion-dollar grant from the National Institute of Allergy and Infectious Diseases. With the development of this nasal spray, Lactiga could potentially address the unmet needs of immunodeficient patients, and help save money for the health care system in the process. And while conditions like "bubble boy disease" are uncommon in the general population, millions of people do have some type of immunodeficiency. Lactiga's goal is to use technology to reduce risk among a range of people who are immu- nocompromised, such as organ transplant recipients and people living with HIV/AIDS. And perhaps it can help alleviate even common symptoms, such as those resulting from respiratory and gastrointestinal infections. "If antibodies could be extracted from milk and then made into purified therapeutic compounds and then delivered to patients who can't make antibodies, could that correct the deficit?" "It could be a transformative paradigm shift for patients who have a very limited set of options," Mane says. "And if this gives them hope, or if they have a new normal because of this, that, to me, is the North Star." Looking back at his journey, Mane is hopeful for the future of science. "Kids who are currently in middle school will be the ones who do something truly disruptive and innovative," he says. "And that's actually very encouraging to me." — Jessie Findlay Today's Lions are tomorrow's leaders. Support their bright future. By contributing to a scholarship fund of your choice, you help ensure that all students, regardless of their background, can receive an exceptional TCNJ education. For additional information, please contact the Office of Development and Alumni Engagement at 800.347.9621 or tcnjfund@tcnj.edu. Make your gift at give.tcnj.edu to support our students. Please give by June 30 to be one of our 2025 fiscal year donors.

• Cover